Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
Harvard Business School
McKesson
AstraZeneca
Dow

Last Updated: June 25, 2022

Covis Company Profile


✉ Email this page to a colleague

« Back to Dashboard

Summary for Covis
International Patents:189
US Patents:17
Tradenames:18
Ingredients:12
NDAs:16

Drugs and US Patents for Covis

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Covis SULAR nisoldipine TABLET, EXTENDED RELEASE;ORAL 020356-005 Jan 2, 2008 AB RX Yes Yes See Plans and Pricing See Plans and Pricing
Covis DUAKLIR PRESSAIR aclidinium bromide; formoterol fumarate POWDER, METERED;INHALATION 210595-001 Mar 29, 2019 RX Yes Yes See Plans and Pricing See Plans and Pricing
Covis ALTOPREV lovastatin TABLET, EXTENDED RELEASE;ORAL 021316-004 Jun 26, 2002 RX Yes Yes See Plans and Pricing See Plans and Pricing
Covis TUDORZA PRESSAIR aclidinium bromide POWDER, METERED;INHALATION 202450-001 Jul 23, 2012 RX Yes Yes RE46417 See Plans and Pricing Y Y See Plans and Pricing
Covis MAKENA hydroxyprogesterone caproate SOLUTION;INTRAMUSCULAR 021945-001 Feb 3, 2011 AP1 RX Yes Yes See Plans and Pricing See Plans and Pricing
Covis BETAPACE AF sotalol hydrochloride TABLET;ORAL 021151-002 Feb 22, 2000 AB RX Yes No See Plans and Pricing See Plans and Pricing
Covis ALTOPREV lovastatin TABLET, EXTENDED RELEASE;ORAL 021316-001 Jun 26, 2002 DISCN No No See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Covis

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Covis SULAR nisoldipine TABLET, EXTENDED RELEASE;ORAL 020356-006 Jan 2, 2008 5,422,123 See Plans and Pricing
Covis ALVESCO ciclesonide AEROSOL, METERED;INHALATION 021658-002 Jan 10, 2008 5,695,743 See Plans and Pricing
Covis SULAR nisoldipine TABLET, EXTENDED RELEASE;ORAL 020356-008 Jan 2, 2008 5,422,123 See Plans and Pricing
Covis ZETONNA ciclesonide AEROSOL, METERED;NASAL 202129-001 Jan 20, 2012 5,775,321 See Plans and Pricing
Covis TUDORZA PRESSAIR aclidinium bromide POWDER, METERED;INHALATION 202450-001 Jul 23, 2012 6,071,498 See Plans and Pricing
Covis SULAR nisoldipine TABLET, EXTENDED RELEASE;ORAL 020356-004 Feb 2, 1995 4,703,038 See Plans and Pricing
Covis ZETONNA ciclesonide AEROSOL, METERED;NASAL 202129-001 Jan 20, 2012 5,683,677 See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for COVIS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Capsules 2 mg, 4 mg and 6 mg ➤ Subscribe 2007-08-10
➤ Subscribe Nasal Spray 250 mcg ➤ Subscribe 2012-02-13
➤ Subscribe Extended-release Tablets 25.5 mg and 34 mg ➤ Subscribe 2008-11-28
➤ Subscribe Extended-release Tablets 8.5 mg and 17 mg ➤ Subscribe 2009-03-02
➤ Subscribe Injection 30 mg/mL, 17 mL single-use vials ➤ Subscribe 2015-12-04
➤ Subscribe Extended-release Tablets 20 mg and 30 mg ➤ Subscribe 2007-11-07
➤ Subscribe Extended-release Tablets 40 mg ➤ Subscribe 2007-06-11

International Patents for Covis Drugs

Country Patent Number Estimated Expiration
Slovenia 2265257 See Plans and Pricing
Denmark 2953667 See Plans and Pricing
New Zealand 585857 See Plans and Pricing
South Africa 200200232 See Plans and Pricing
Denmark 2954891 See Plans and Pricing
South Korea 100854321 See Plans and Pricing
World Intellectual Property Organization (WIPO) 2006079064 See Plans and Pricing
>Country >Patent Number >Estimated Expiration

Supplementary Protection Certificates for Covis Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1169062 1290043-7 Sweden See Plans and Pricing PRODUCT NAME: FERUMOXYTOL; REG. NO/DATE: EU/1/12/774/001 20120615
1411900 SPC/GB11/015 United Kingdom See Plans and Pricing PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105
1200431 2013C/001 Belgium See Plans and Pricing PRODUCT NAME: SEL D'ACLIDINIUM AVEC UN ANION PHARMACEUTIQUEMENT ACCEPTABLE D'UN ACIDE MONO OU POLYVALENT EN PARTICULIER LE BROMURE D'ACLIDINIUM; AUTHORISATION NUMBER AND DATE: EU/1/12/781/001 20120725
1411900 2011C/016 Belgium See Plans and Pricing PRODUCT NAME: NAPROXENE ET ESOMEPRAZOLE (SOUS LA FORME D'ESOMEPRAZOLE MAGNESIUM TRIHYDRATE); AUTHORISATION NUMBER AND DATE: BE382505 20101214
1200431 C01200431/01 Switzerland See Plans and Pricing PRODUCT NAME: ACLIDINIUM; REGISTRATION NO/DATE: SWISSMEDIC 62590 25.04.2013
1200431 1390002-2 Sweden See Plans and Pricing PRODUCT NAME: AKLIDINIUMSALT MED FARMACEUTISKT ACCEPTABEL ANJON AV EN- ELLER FLERVAERD SYRA, SPECIELLT AKLIDINIUMBROMID; REG. NO/DATE: EU/1/12/778/001 20120720
1169062 2012C/052 Belgium See Plans and Pricing PRODUCT NAME: FERUMOXYTOL; AUTHORISATION NUMBER AND DATE: EU/1/12/774/001 20120620
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Mallinckrodt
Johnson and Johnson
McKinsey
Boehringer Ingelheim
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.